China Universal Asset Management Company’s Enanta Pharmaceuticals ENTA Stock Holding History

China Universal Asset Management Company’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$67.5K	Sell	4,628 -522	-10%	-$7.02K	﹤0.01%	443
2026 Q1	$65K	Buy	5,150 +447	+10%	+$5.99K	﹤0.01%	445
2025 Q4	$74.2K	Sell	4,703 -4,044	-46%	-$51.4K	0.01%	426
2025 Q3	$105K	Buy	8,747 +4,454	+104%	+$35.6K	0.01%	386
2025 Q2	$32.5K	Buy	4,293 +14	+0.3%	+$84	﹤0.01%	440
2025 Q1	$23.6K	Sell	4,279 -215	-5%	-$1.33K	﹤0.01%	453
2024 Q4	$25.8K	Buy	+4,494	New	+$43.1K	﹤0.01%	479
2023 Q4	–	Sell	-548	Closed	-$6.12K	–	444
2023 Q3	$6.12K	Buy	548 +272	+99%	+$4.38K	﹤0.01%	380
2023 Q2	$5.91K	Sell	276 -7	-2%	-$206	﹤0.01%	356
2023 Q1	$11.4K	Buy	283 +72	+34%	+$3.44K	﹤0.01%	277
2022 Q4	$9.82K	Buy	211 +17	+9%	+$775	﹤0.01%	229
2022 Q3	$10K	Buy	+194	New	+$11.3K	﹤0.01%	205

Other funds holding ENTA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCIA

Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

China Universal Asset Management Company's ENTA Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Enanta Pharmaceuticals (ENTA) stake by 10% in Q2 2026, selling an estimated $7.02K and leaving 4,628 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

China Universal Asset Management Company first reported a position in ENTA in Q3 2022 and has held it in 12 quarters since. The position peaked at $105K in Q3 2025. 61 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

China Universal Asset Management Company held 4,628 shares of Enanta Pharmaceuticals worth $67.5K as of Q2 2026.
China Universal Asset Management Company sold 522 Enanta Pharmaceuticals shares in Q2 2026, an estimated $7.02K.
Enanta Pharmaceuticals made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #443 holding.
China Universal Asset Management Company first reported a position in Enanta Pharmaceuticals in Q3 2022 and has held it in 12 quarters since.
China Universal Asset Management Company's Enanta Pharmaceuticals position peaked at $105K in Q3 2025.
61 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.